866-997-4948(US-Canada Toll Free)

Diarrhea - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 146 Pages

Diarrhea - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H2 2017, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 10, 2, 1, 21 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 4 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diarrhea (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diarrhea - Overview 7
Diarrhea - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 13
Products under Development by Companies 14
Products under Development by Universities/Institutes 17
Diarrhea - Therapeutics Assessment 18
Assessment by Target 18
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Diarrhea - Companies Involved in Therapeutics Development 27
A. Menarini Industrie Farmaceutiche Riunite Srl 27
Actelion Ltd 27
Aegis Therapeutics LLC 28
Akthelia Pharmaceuticals Ltd 28
Albireo Pharma Inc 29
Allergan Plc 29
Anatara Lifesciences Limited 30
Ardelyx Inc 30
Assembly Biosciences Inc 31
AzurRx BioPharma Inc 31
Bharat Biotech International Ltd 32
Cosmo Pharmaceuticals NV 32
DiscoveryBiomed Inc 33
GP Pharm SA 33
Miyarisan Pharmaceutical Company Ltd 34
Mucosis BV 34
Napo Pharmaceuticals Inc 35
Nippon Shinyaku Co Ltd 35
Novartis AG 36
Pfizer Inc 36
Prokarium Ltd 37
Rebiotix Inc 37
Recce Ltd 38
RedHill Biopharma Ltd 38
RxBio Inc 39
Scandinavian Biopharma Holding AB 39
Sigmoid Pharma Ltd 40
Summit Therapeutics Plc 40
Synthetic Biologics Inc 41
Syntiron LLC 41
Tasly Pharmaceutical Group Co Ltd 42
Wuhan Institute of Biological Products Co Ltd 42
Diarrhea - Drug Profiles 43
ABIM-101 - Drug Profile 43
AKT-10081 - Drug Profile 44
ASP-7147 - Drug Profile 45
AZX-1101 - Drug Profile 46
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 47
cadazolid - Drug Profile 48
Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile 50
CBM-588 - Drug Profile 52
cholestyramine - Drug Profile 54
crofelemer DR - Drug Profile 56
Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 60
Escherichia coli vaccine - Drug Profile 61
ETEC vaccine - Drug Profile 62
ETEC vaccine - Drug Profile 63
Etvax - Drug Profile 64
GXG-8 - Drug Profile 66
ibodutant - Drug Profile 67
IMSUTMR-1501 - Drug Profile 68
infectious diarrhea [serotype H11] vaccine - Drug Profile 69
LJN-452 - Drug Profile 70
octreotide acetate - Drug Profile 71
octreotide acetate MAR - Drug Profile 72
ondansetron hydrochloride CR - Drug Profile 73
ORP-101 - Drug Profile 80
Peptide to Activate NHE-3 for Diarrhea - Drug Profile 81
PF-06425090 - Drug Profile 82
prulifloxacin - Drug Profile 84
PZ-7475 - Drug Profile 86
RBX-2660 - Drug Profile 87
RDX-023 - Drug Profile 91
RDX-98940 - Drug Profile 92
RECCE-355 - Drug Profile 93
Recombinant Enzyme for Diarrhea - Drug Profile 94
ribaxamase - Drug Profile 95
ridinilazole - Drug Profile 101
rifamycin CR - Drug Profile 108
Rotavac-5C - Drug Profile 111
rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile 112
Rx-100 - Drug Profile 113
Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 115
Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 116
Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile 117
SYN-006 - Drug Profile 118
SYN-007 - Drug Profile 119
thuricin CD - Drug Profile 120
Typhetec - Drug Profile 121
Vaccine 1 for Diarrhea - Drug Profile 122
Vaccine 2 for Diarrhea - Drug Profile 123
Vaccine for Traveler's Diarrhea - Drug Profile 124
Vaccine for Traveler's Diarrhea - Drug Profile 125
Yersinia pestis vaccine - Drug Profile 126
Diarrhea - Dormant Projects 127
Diarrhea - Discontinued Products 130
Diarrhea - Product Development Milestones 131
Featured News & Press Releases 131
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

List of Tables
Number of Products under Development for Diarrhea, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2017
Diarrhea - Pipeline by Actelion Ltd, H2 2017
Diarrhea - Pipeline by Aegis Therapeutics LLC, H2 2017
Diarrhea - Pipeline by Akthelia Pharmaceuticals Ltd, H2 2017
Diarrhea - Pipeline by Albireo Pharma Inc, H2 2017
Diarrhea - Pipeline by Allergan Plc, H2 2017
Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2017
Diarrhea - Pipeline by Ardelyx Inc, H2 2017
Diarrhea - Pipeline by Assembly Biosciences Inc, H2 2017
Diarrhea - Pipeline by AzurRx BioPharma Inc, H2 2017
Diarrhea - Pipeline by Bharat Biotech International Ltd, H2 2017
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, H2 2017
Diarrhea - Pipeline by DiscoveryBiomed Inc, H2 2017
Diarrhea - Pipeline by GP Pharm SA, H2 2017
Diarrhea - Pipeline by Miyarisan Pharmaceutical Company Ltd, H2 2017
Diarrhea - Pipeline by Mucosis BV, H2 2017
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, H2 2017
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, H2 2017
Diarrhea - Pipeline by Novartis AG, H2 2017
Diarrhea - Pipeline by Pfizer Inc, H2 2017
Diarrhea - Pipeline by Prokarium Ltd, H2 2017
Diarrhea - Pipeline by Rebiotix Inc, H2 2017
Diarrhea - Pipeline by Recce Ltd, H2 2017
Diarrhea - Pipeline by RedHill Biopharma Ltd, H2 2017
Diarrhea - Pipeline by RxBio Inc, H2 2017
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2017
Diarrhea - Pipeline by Sigmoid Pharma Ltd, H2 2017
Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2017
Diarrhea - Pipeline by Synthetic Biologics Inc, H2 2017
Diarrhea - Pipeline by Syntiron LLC, H2 2017
Diarrhea - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, H2 2017
Diarrhea - Dormant Projects, H2 2017
Diarrhea - Dormant Projects, H2 2017 (Contd..1), H2 2017
Diarrhea - Dormant Projects, H2 2017 (Contd..2), H2 2017
Diarrhea - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Diarrhea, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *